ANDA 85317, held by Watson Labs. Hydrochlorothiazide; Reserpine.
As of Nov 16, 2026, ANDA 85317 (Hydrochlorothiazide W/ Reserpine), held by Watson Labs, was not approved, with 0 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydrochlorothiazide W/ Reserpine25MG;0.125MG ยท tablet;oral | Hydrochlorothiazide; Reserpine | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters